Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology’s (ACG) Annual Meeting
ARDX 10.28.2024
Ninety percent of survey participants reported “some” or “significant” negative impact of IBS-C on their life
Survey results presented in two poster presentations
“Ardelyx is committed to better understanding the lived experience of patients with IBS-C, and the insights gained from our IBS in America supplemental survey clearly outline the everyday impact of IBS-C on patients, which extends far beyond constipation and results in a low quality of life for many patients,” said
Notably, 90% of IBS-C patients surveyed reported “some” or “significant” negative impact of IBS-C on their life, with a majority indicating they feel a negative impact on their mental and emotional health, sexual health and intimacy, relationships and sense of independence. More than one-third of IBS-C patients described their quality of life as “poor” or “fair,” often attributed to having multiple health conditions. The comorbidities most experienced and reported included mental health conditions, chronic pain conditions, metabolic disorders and other gastrointestinal disorders.
A Media Snippet accompanying this announcement is available by clicking on this link.
Additional survey findings include:
- 85% of patients experienced pain in the rectum or anus while trying to have bowel movements
- Over 55% of patients reported a feeling of incomplete bowel movement “often” or “always” in the previous seven days
- Most of those surveyed experienced other symptoms in addition to constipation, including:
- 86% of patients experienced bloating
- 85% of patients experienced abdominal cramps and pain
- 64% of patients experienced fatigue
- Of the 104 respondents currently perimenopausal or having menstrual periods, more than 45% felt that menstruation made constipation worse, and over 80% felt menstruation exacerbated abdominal pain and bloating symptoms
- Over 45% of patients considered IBS-C “somewhat,” “quite a bit” or “very much” a financial hardship to themselves and their families
Data from the IBS in America 2024 supplemental survey was presented in two posters during ACG’s Annual Scientific Meeting this week, which are publicly availablehere.
Title:Irritable Bowel Syndrome With Constipation Poses a Substantial Burden to Patient Overall Health Status and Quality of Life: Results From the IBS In America 2024
Title:Patients With Irritable Bowel Syndrome With Constipation From the IBS In America 2024 Real-World Survey Experience Burdensome Symptoms Beyond ConstipationAuthors:
About Irritable Bowel Syndrome with Constipation (IBS-C)Irritable bowel syndrome with constipation (IBS-C) is a gastrointestinal disorder characterized by both abdominal pain and altered bowel movements, estimated to affect 12 million people in the
About IBS in America 2024IBS in America 2024 was a 15-minute, real-world, online survey fielded by
Four questions addressed patients’ menstrual status and the impact of menstruation on constipation. These analyses only include patients diagnosed with IBS-C who completed the supplemental extension survey. Respondents with IBS-C (N=284) had a mean (range) age of 51 (18-86) years and were predominantly female (92%; 48% postmenopausal) and White (87%). Most respondents had been living with IBS-C for ≥2 years, and 80% of respondents reported IBS episodes occurring weekly or daily over the past year. This survey was designed to learn about patients’ experience with IBS-C and did not investigate safety or efficacy of any prescription drugs for management of IBS-C.
About
About
Investor and Media Contacts:
Source: Ardelyx, Inc.